James P. Ohr
Experienced in WT1-Related Wilms Tumor Syndromes

Dr. James P. Ohr

Hematology Oncology
UPMC
UPMC Hillman Cancer Center - Erie
2500 West 12th Street, 
Erie, PA 
On Staff At
Accepting New Patients
Offers Telehealth

Experienced in WT1-Related Wilms Tumor Syndromes
UPMC
UPMC Hillman Cancer Center - Erie
2500 West 12th Street, 
Erie, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

James P. Ohr, DO, is a medical oncologist and hematologist at UPMC Hillman Cancer Center. He has a clinical interest in gastrointestinal malignancies, peritoneal carcinomas, and head and neck malignancies.

Dr. Ohr is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Throat Cancer, Laryngeal Cancer, Pancreatic Cancer, and Gastrostomy.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Philadelphia College Of Osteopathic Medicine
Residency
Western Pennsylvania Hospital
Specialties
Hematology Oncology
Licenses
Internal Medicine in PA
Board Certifications
American Board Of Internal Medicine
Fellowships
Western Pennsylvania Hospital
Hospital Affiliations
Upmc Northwest
Upmc Hamot
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Univera Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

UPMC Hillman Cancer Center - Erie
2500 West 12th Street, Erie, PA 16505
Call: 814-836-2600

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


12 Clinical Trials

Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Afatinib Dimaleate, Cetuximab
Study Phase: Phase 2/Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 27, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Phase II Study for Curative Intent Treatment for Patients With Oligometastatic Disease at Initial Presentation
Enrollment Status: Terminated
Publish Date: October 11, 2023
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: June 05, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cetuximab, Docetaxel
Study Phase: Phase 2
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Phase II Study of Stereotactic Radiosurgery for Patients With Oligo-recurrent Disease
Enrollment Status: Completed
Publish Date: May 19, 2023
Intervention Type: Radiation
Study Phase: Not Applicable
A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Enrollment Status: Completed
Publish Date: April 13, 2022
Intervention Type: Device
Study Phase: Not Applicable
Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay
Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay
Enrollment Status: Completed
Publish Date: February 17, 2022
Intervention Type: Other, Drug
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers
Enrollment Status: Unknown
Publish Date: October 26, 2021
Intervention Type: Drug
Study Drug: Enzalutamide
Study Phase: Phase 2
View 11 Less Clinical Trials

41 Total Publications

Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer.
Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 27, 2025
View All 41 Publications
Similar Doctors
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Shinoj P. Pattali-Jayavalsan
Hematology Oncology | Hematology | Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Shinoj P. Pattali-Jayavalsan
Hematology Oncology | Hematology | Oncology

Ashtabula County Medical Center

2420 Lake Ave, 
Ashtabula, OH 
 (108.0 miles away)
440-997-6969
Languages Spoken:
English, Burmese, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Shinoj Pattali-Jayavalsan is a Hematologist Oncology specialist and a Hematologist in Ashtabula, Ohio. Dr. Pattali-Jayavalsan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Iron Deficiency Anemia, Saddle Pulmonary Embolism, Childhood Iron Deficiency Anemia, Familial Colorectal Cancer, and Bone Marrow Aspiration. Dr. Pattali-Jayavalsan is currently accepting new patients.

David J. Seastone
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. David J. Seastone
Hematology Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. David J. Seastone
Hematology Oncology

UPMC Hillman Cancer Center - Erie

2500 West 12th Street, 
Erie, PA 
 (114.4 miles away)
814-836-2600
Experience:
16+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David James Seastone, DO, PhD, is a medical oncologist and treats all medical oncology and hematology cases. Dr. Seastone is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Bone Marrow Aspiration.

Jan M. Rothman
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Jan M. Rothman
Hematology Oncology
Experienced in WT1-Related Wilms Tumor Syndromes
Dr. Jan M. Rothman
Hematology Oncology

UPMC Hillman Cancer Center - Erie

2500 West 12th Street, 
Erie, PA 
 (114.4 miles away)
814-836-2600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jan M. Rothman, MD, is a medical oncologist and treats all medical oncology and hematology cases. Dr. Rothman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Mantle Cell Lymphoma (MCL), Lung Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ohr's expertise for a condition
ConditionClose
  • Elite
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dr. Ohr is
    Elite
    . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
    See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
  • Distinguished
  • Colorectal Cancer
    Dr. Ohr is
    Distinguished
    . Learn about Colorectal Cancer.
    See more Colorectal Cancer experts
  • Familial Pancreatic Cancer
    Dr. Ohr is
    Distinguished
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Laryngeal Cancer
    Dr. Ohr is
    Distinguished
    . Learn about Laryngeal Cancer.
    See more Laryngeal Cancer experts
  • Pancreatic Cancer
    Dr. Ohr is
    Distinguished
    . Learn about Pancreatic Cancer.
    See more Pancreatic Cancer experts
  • Throat Cancer
    Dr. Ohr is
    Distinguished
    . Learn about Throat Cancer.
    See more Throat Cancer experts
  • Advanced
  • Acinic Cell Carcinoma of Salivary Glands
    Dr. Ohr is
    Advanced
    . Learn about Acinic Cell Carcinoma of Salivary Glands.
    See more Acinic Cell Carcinoma of Salivary Glands experts
  • Adenoid Cystic Carcinoma
    Dr. Ohr is
    Advanced
    . Learn about Adenoid Cystic Carcinoma.
    See more Adenoid Cystic Carcinoma experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Ohr is
    Advanced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • EGFR Positive Lung Cancer
    Dr. Ohr is
    Advanced
    . Learn about EGFR Positive Lung Cancer.
    See more EGFR Positive Lung Cancer experts
  • Epithelial-Myoepithelial Carcinoma
    Dr. Ohr is
    Advanced
    . Learn about Epithelial-Myoepithelial Carcinoma.
    See more Epithelial-Myoepithelial Carcinoma experts
  • Familial Colorectal Cancer
    Dr. Ohr is
    Advanced
    . Learn about Familial Colorectal Cancer.
    See more Familial Colorectal Cancer experts
View All 23 Advanced Conditions
  • Experienced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Ohr is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Ohr is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Ohr is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Adrenal Cancer
    Dr. Ohr is
    Experienced
    . Learn about Adrenal Cancer.
    See more Adrenal Cancer experts
  • Adult Soft Tissue Sarcoma
    Dr. Ohr is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Ohr is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
View All 121 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2025 All Rights Reserved